2. Academic Validation
  3. Bicyclic [3.3.0]-Octahydrocyclopenta[c]pyrrolo Antagonists of Retinol Binding Protein 4: Potential Treatment of Atrophic Age-Related Macular Degeneration and Stargardt Disease

Bicyclic [3.3.0]-Octahydrocyclopenta[c]pyrrolo Antagonists of Retinol Binding Protein 4: Potential Treatment of Atrophic Age-Related Macular Degeneration and Stargardt Disease

  • J Med Chem. 2015 Aug 13;58(15):5863-88. doi: 10.1021/acs.jmedchem.5b00423.
Christopher L Cioffi,  Boglarka Racz 1,  Emily E Freeman,  Michael P Conlon,  Ping Chen,  Douglas G Stafford,  Daniel M C Schwarz,  Lei Zhu,  Douglas B Kitchen,  Keith D Barnes,  Nicoleta Dobri 1,  Enrique Michelotti 2,  Charles L Cywin 3,  William H Martin 4,  Paul G Pearson 5,  Graham Johnson 5,  Konstantin Petrukhin 1
Affiliations

Affiliations

  • 1 §Department of Ophthalmology, Columbia University Medical Center, New York, New York 10032, United States.
  • 2 #National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892, United States.
  • 3 ○National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, United States.
  • 4 ⊥WHM Consulting LLC, 111 Sterling City Road, Lyme, Connecticut 06371, United States.
  • 5 ∥iCuraVision LLC, 31194 La Baya Drive, Suite 101, Westlake Village, California 91362, United States.
PMID: 26181715 DOI: 10.1021/acs.jmedchem.5b00423
Abstract

Antagonists of retinol-binding protein 4 (RBP4) impede ocular uptake of serum all-trans retinol (1) and have been shown to reduce cytotoxic bisretinoid formation in the retinal pigment epithelium (RPE), which is associated with the pathogenesis of both dry age-related macular degeneration (AMD) and Stargardt disease. Thus, these agents show promise as a potential pharmacotherapy by which to stem further neurodegeneration and concomitant vision loss associated with geographic atrophy of the macula. We previously disclosed the discovery of a novel series of nonretinoid RBP4 antagonists, represented by bicyclic [3.3.0]-octahydrocyclopenta[c]pyrrolo analogue 4. We describe herein the utilization of a pyrimidine-4-carboxylic acid fragment as a suitable isostere for the anthranilic acid appendage of 4, which led to the discovery of standout antagonist 33. Analogue 33 possesses exquisite in vitro RBP4 binding affinity and favorable drug-like characteristics and was found to reduce circulating plasma RBP4 levels in vivo in a robust manner (>90%).

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z